StreetInsider.com News Articles

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:05:00 -0400

HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have an exercise price of $34.30 per share, which is equal to the closing price of the Company’s

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 02 Jun 2026 16:05:00 -0400

The stock options that were granted have an exercise price of $34.30 per share, which is equal to the closing price of the Company’s

vTv Therapeutics (VTVT) PT Lowered to $45 at H.C. Wainwright

Thu, 14 May 2026 06:44:38 -0400

(Updated - May 14, 2026 6:44 AM EDT)

H.C. Wainwright analyst Emily Bodnar lowered the price target on vTv Therapeutics (NASDAQ: VTVT) to $45.00 (from $47.00) while maintaining a Buy rating.

The analyst commented: "Yesterday after market close, vTv reported 1Q26 earnings and provided a corporate update, reiterating enrollment timelines. We remind, in March, the company updated its enrollment guidance for the CATT1 trial evaluating cadisegliatin (cadi) in Type 1 Diabetes (T1D) as an insulin adjuvant therapy, shifting from completion in 1H26 to 3Q26. The trial (NCT06334133) is now actively enrolling and dosing patients across 56 sites, which is in-line with management's

vTv Therapeutics (VTVT) PT Lowered to $45 at H.C. Wainwright

Thu, 14 May 2026 06:44:38 -0400

(Updated - May 14, 2026 6:44 AM EDT)

H.C. Wainwright analyst Emily Bodnar lowered the price target on vTv Therapeutics (NASDAQ: VTVT) to $45.00 (from $47.00) while maintaining a Buy rating.

Form 424B2 vTv Therapeutics Inc.

Wed, 13 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260513/26487618.html

Form 424B2 vTv Therapeutics Inc.

Wed, 13 May 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260513/26487618.html

Form 8-K vTv Therapeutics Inc. For: May 13

Wed, 13 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260513/26487597.html

Form 8-K vTv Therapeutics Inc. For: May 13

Wed, 13 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260513/26487597.html

Form S-8 vTv Therapeutics Inc.

Wed, 13 May 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260513/26487573.html

Form S-8 vTv Therapeutics Inc.

Wed, 13 May 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260513/26487573.html

Form 10-Q vTv Therapeutics Inc. For: Mar 31

Wed, 13 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260513/26486486.html

Form 10-Q vTv Therapeutics Inc. For: Mar 31

Wed, 13 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260513/26486486.html

Form 8-K vTv Therapeutics Inc. For: May 13

Wed, 13 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260513/26486373.html

Form 8-K vTv Therapeutics Inc. For: May 13

Wed, 13 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260513/26486373.html

vTv Therapeutics (VTVT) Tops Q1 EPS by 165c

Wed, 13 May 2026 16:19:25 -0400

vTv Therapeutics (NASDAQ: VTVT) reported Q1 EPS of $1.65. Revenue for the quarter came in at $36.84 million.

For earnings history and earnings-related data on vTv Therapeutics (VTVT) click here.

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:01:00 -0400

Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026

Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout

HIGH POINT, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. The Company continues to advance its Phase 3

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Wed, 13 May 2026 16:01:00 -0400

Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026

Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 08 May 2026 16:15:00 -0400

HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 39,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have a weighted average exercise price of $32.00 per share. Each option award will vest over a 4-year

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 08 May 2026 16:15:00 -0400

The stock options that were granted have a weighted average exercise price of $32.00 per share. Each option award will vest over a 4-year

vTv Therapeutics to Participate in Upcoming May Investor Conferences

Thu, 07 May 2026 08:00:00 -0400

HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May:

H.C. Wainwright 4th Annual BioConnect Investor Conference
Format: Fireside Chat & one-on-one investor meetings
Date: Tuesday, May 19, 2026
Time: 12:30 PM ET
Location: New York, NY
Webcast Link